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March 2020 Biochemical Transitions in PBC 685proportions of these patients who then transitioned to advanced PBC at 1, 3, and 5 years
later were 3.4%, 12.5%, and 16.0%, respectively. During the follow-up period, 236 patients
had a clinical event. The proportions of patients with moderate PBC and event-free survival
were 97.9%, 95.1%, and 91.5% at 1, 3, and 5 years, respectively, and the proportions of
patients with advanced PBC and event-free survival were 90.6%, 71.2%, and 58.3% at 1, 3,
and 5 years later, respectively. Variables associated with transition from early to moderate
PBC included baseline levels of bilirubin, albumin, and alkaline phosphatase; aspartate to
alanine aminotransferase ratio; platelet count; and treatment with ursodeoxycholic acid.
Transitions from early to moderate PBC and from moderate to advanced PBC were associ-
ated with higher probabilities of a clinical event (time-dependent hazard ratios, 3.0; 95% CI,
2.0–4.5; and 4.6; 95% CI, 3.5–6.2).CONCLUSIONS: Approximately half of patients with early stage PBC progress to a more severe stage within 5
years. Progression is associated with an increased risk of a clinical event, so surveillance is
important for patients with early stage PBC.Keywords: Autoimmune Liver Disease; Prognostic Factor; Antimitochondrial Antibodies; UDCA.Primary biliary cholangitis (PBC) is a slowlyprogressive cholestatic liver disease that may
lead to cirrhosis and liver failure, requiring liver
transplantation (LT). Currently, ursodeoxycholic acid
(UDCA) is the first-line therapy, but new therapies are
becoming available.1
The clinical course of PBC varies greatly, and its
clinical presentation has changed substantially over
recent decades. In the past, most patients were diag-
nosed at symptomatic and advanced disease stages
(extensive fibrosis or cirrhosis),2 but the majority of
PBC patients seen in recent clinical practice are diag-
nosed at asymptomatic and earlier stages.3–5 This shift
in clinical presentation may be owing to higher disease
awareness,1 improved diagnostic assays for anti-
mitochondrial antibody detection,6 and/or more
routine testing of liver function tests. Regardless, given
the shift, relying solely on hard clinical end points,
such as death or LT, may not be feasible in clinical
studies of patients with PBC.7
The long-term survival of PBC patients with an
early biochemical stage (defined as normal albumin
and normal bilirubin levels based on the Rotterdam
criteria) generally is comparable with the survival rate
of the general population.8 These patients therefore
are perceived as having a low risk of developing pro-
gressive disease. However, patients identified as low
risk at the beginning of the disease still may progress
to a moderate (abnormal albumin or bilirubin levels)
or advanced stage (both abnormal albumin and bili-
rubin levels) during follow-up evaluation, which may
be associated with worse long-term survival. Knowl-
edge regarding predictive factors for biochemical
transitions, as well as their impact on prognosis, may
aid in identifying patients who are likely to progress
over time. Therefore, in a cohort of PBC patients with
early biochemical stage, we examined the proportion
who progressed to moderate or advanced PBC and
factors associated with progression and patient
survival.Methods
Patients
This study was a subgroup analysis of patients
included in the Global PBC Study Group (GPBCSG)
database, a multicenter collaboration between 19 liver
centers from 12 North American and European coun-
tries. All patients had an established diagnosis of PBC.1
Follow-up data were collected prospectively.
For the current study, only those patients with bio-
chemically early disease at baseline according to the
Rotterdam criteria9 were included and evaluated for
transition to biochemically moderate and/or advanced
disease during follow-up evaluation. Both UDCA-treated
and untreated patients were included. Exclusion
criteria and collected data are listed in the
Supplementary Methods section.
This study was conducted in accordance with the
protocol and principles of the 1975 Declaration of Hel-
sinki. The protocol was approved by the Institutional
Research Board of the corresponding center, and at each
participating center, in accordance with local regulations.
End Points
The end points included progression to moderate PBC
(abnormal level of bilirubin or albumin) or advanced-
stage PBC (abnormal level of both bilirubin and albu-
min) and progression to the composite clinical end point,
defined by either LT, ascites, variceal bleeding, hepatic
encephalopathy, development of hepatocellular carci-
noma, or death, whichever occurred first.
Statistical Analysis
The baseline visit was considered as the start date of
UDCA or the date of initial evaluation in case of untreated
patients. A competing-risk approach was used: patients
What You Need to Know
Background
Patients usually receive a diagnosis of primary
biliary cholangitis (PBC) at an early stage. We stud-
ied the proportion of patients who progress to
moderate or advanced PBC, factors associated with
progression, and patient survival.
Findings
Approximately half of patients with early stage PBC
progress to a more severe stage within 5 years.
However, most patients with moderate or advanced
PBC survive until this time point. We identified
biochemical and treatment factors associated with
the progression of PBC.
Implications for patient care
The progression of PBC is associated with an
increased risk of a clinical event, so surveillance is
important for patients with early stage PBC.
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follow-up evaluation or patients who did not reach any
of the components of the composite clinical event were
censored at their last follow-up visit. To determine the
overall impact of transitions between biochemical stages
on event-free survival, the time until patients transi-
tioned from early to moderate stage, and early to
advanced biochemical stage, was modeled as a time-
dependent covariate.
Biochemical data were not available for all patients.
Missing data varied between 8% for alkaline phosphatase
(ALP) and 26.6% for aspartate aminotransferase (AST)
values; it is probable that stable patients had fewer lab-
oratory measurements, contrary to the closer follow-up
evaluation of patients with an accelerated progression,
thereby creating a bias in the availability of data. Because
of the extensive data collection effort for the GPBCSG,
laboratory data were available for a total of 75,000 visits
between UDCA initiation/date of initial evaluation until
the end of follow-up evaluation or the occurrence of a
clinical event. As such, the trajectory of the laboratory
values over time was used as prior information for the
imputation of missing values as well as the strong cor-
relation between multiple different laboratory values and
the end point. Therefore, we used an imputed data set for
our primary analysis to ensure full detection of
biochemical transitions. In detail, SAS (SAS multiple
imputation procedure, Markov Chain Monte Carlo
(MCMC) method; SAS software, version 9.3, SAS Institute,
Cary, NC) was used to generate 10 imputed data sets of
laboratory results at yearly time points between the start
of UDCA treatment or the initial evaluation and up to 15
years of follow-up evaluation. Missing data were consid-
ered as missed at random. Rubin’s rule10,11 rules were
used for estimation of the parameters and the standard
error. The imputation model included baseline variables
that were potentially predictive of PBC outcomes (eg, year
of diagnosis, age) as well as the outcomes themselves.
Only continuous biochemical variables were imputed.
Univariate and multivariate Cox regression analyses
were performed to assess the impact of various factors
on the rate of biochemical transition from biochemically
early to moderate disease, and from moderate to
advanced disease. In the analyses of factors associated
with transition from moderate to advanced disease,
laboratory parameters correspond to the time point of
moderate disease development. In multivariable ana-
lyses, the model with the lowest Akaike Information
Criteria was chosen. The effect of albumin and bilirubin
within the normal range are presented on a continuous
scale and by a binary split at the median for reasons of
clinical interpretation and the aim of comparing groups
of equal sample size. In addition, transition rates were
assessed and compared between patients with baseline
GLOBE scores above the age-specific GLOBE score
threshold, and those remaining below this threshold
using Kaplan–Meier estimates. The calculation and use of
GLOBE score thresholds have been described previously,with patients above the threshold presenting a signifi-
cantly worse survival compared with matched in-
dividuals from the general population.12
Normally distributed data are presented as means 
SD, and skewed distributed data are presented as median
and interquartile range (IQR). Where indicated, contin-
uous variables underwent natural logarithmic trans-
formation to correct for nonlinearity. All analyses were
2-sided. A P value less than .05 was considered statisti-
cally significant. Statistics analyses were performed with
IBM SPSS Statistics 22.0 (SPSS, Inc, Chicago, IL).Results
Study Population Characteristics
The patient population consisted of 1615 patients with
biochemically early PBC (Supplementary Figure 1). The
mean age at study entry was 55.4 years (SD, 11.9 y). The
median total follow-upperiodwas7.9 years (IQR, 4.3–12.5
y; range, 0.5–25 y). Baseline patient characteristics are
shown in Table 1. The majority of patients (1415 of 1615;
87.6%) were treated with UDCA. Histologic disease stage
(according to the Ludwig et al13 and Scheuer14 classifica-
tion) was available for 798 (49%) patients, of whommost
had early disease (stages I or II, 623 of 798; 78%).
Of the 1415 UDCA-treated patients, a total of 1383 had
a follow-up period that was longer than 1 year, with
biochemical nonresponse rates, according to various
criteria, ranging from 14.0% with the Paris I criteria to
59.9%with theBarcelona criteria. According to theGLOBE
score, only 11.0% of patients presenting with early stage
PBC had an estimated survival rate that was worse than
that of the general population at 1 year of UDCA therapy.
Table 1. Baseline Study Population Characteristics
Total cohort (N ¼ 1615)
Age at diagnosis, y 53.4 (12.0)
Age at study entry, y 55.4 (11.9)
Year of diagnosis, median (IQR) 1997 (1990–2004)
Year of diagnosis, range 1961–2014
Female, n (%) 1480 (91.6)
AMAþ, n (%) 1459 (90.3)
UDCA treated, n (%) 1415 (87.6)





Serum total bilirubin level, ULN 0.52 (0.40–0.70)
Serum albumin level, LLN 1.19 (1.11–1.26)
Serum ALP level, ULN 1.93 (1.25–3.11)
Serum AST level, ULN 1.28 (0.90–1.87)
Serum ALT level, ULN 1.50 (0.95–2.33)
Serum platelets, 103/mm3 255 (203–366)
NOTE. Data are represented as means (SD) and medians (IQR).
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMA, anti-
mitochondrial antibodies; AST, aspartate aminotransferase; IQR, interquartile
range; LLN, lower limit of normal; UDCA, ursodeoxycholic acid; ULN, upper
limit of normal.
aBaseline biopsy specimens (obtained within 1 year of start of UDCA) were
available in 798 of 1615 (49%) patients. Histologic stage is determined
according to the Ludwig et al13 and Scheuer14 classification.
March 2020 Biochemical Transitions in PBC 687Transitions in Biochemical Stage
During the median of 7.9 years (IQR, 4.3–12.5 y) of
follow-up evaluation, 904 patients transitioned from
biochemically early to moderately advanced stage.Figure 1. Transitions of patients according to their biochemical
four patients transitioned directly to advanced stage. For thes
moderate to advanced stages. bEight cirrhotic decompensatio
cirrhotic decompensations, 11 HCC, 7 LTx, and 47 deaths (7 live
34 deaths (9 liver-related). HCC, hepatocellular carcinoma, LTxSequentially, 201 of 904 patients transitioned from
moderate to advanced disease (Figure 1). Thirty-four
patients transitioned directly from early to advanced
stage. For these patients, we assumed that the transition
took place via moderate stage. Overall, the transition
rates from early to moderate stage were 12.9% at 1 year,
30.2% at 3 years, and 45.8% at 5 years of follow-up
evaluation (Figure 2A). The cumulative transition rates
from moderate to advanced (201 of 904) stage were
3.4% at 1 year, 12.5% at 3 years, and 16.0% at 5 years of
follow-up evaluation (Figure 2B). The median time to
transition to moderate stage was 2.5 years (IQR, 1–5 y;
range, 0.5–15 y). The median time from moderate to
advanced stage was 1.5 years (IQR, 0.5–3.5 y; range,
0.5–11.5 y).Factors Associated With Transition From
Biochemical Early to Moderately Advanced
Disease Stage
In univariate analyses, baseline factors associated
with progression from biochemically early to moderate
disease were male sex, older age at study entry, bilirubin
level, albumin level, ALP level, and AST/alanine amino-
transferase (ALT) ratio. Patients with a more recent
diagnosis and higher platelet levels at baseline and were
less likely to transition to moderate stage (Table 2). Bi-
opsy (available for 798 patients) stages III and IV were
associated with a higher probability of disease progres-
sion compared with stage I (hazard ratio [HR], 1.7; 95%
CI, 1.3–2.2; P < .001; and HR, 1.8; 95% CI, 1.3–2.5; P <
.001, respectively), while stage II was not associated withstage during follow-up evaluation and clinical events. aThirty-
e patients, we assumed they transitioned gradually through
ns, no HCC, no LTx, and 31 deaths (5 liver-related). cForty
r-related). dThirty-nine decompensations, 8 HCC, 11 LTx, and
, liver transplantation.
Figure 2. Cumulative incidence of biochemical transition and
events. Kaplan–Meier estimates of (A) transition from mild to
a moderate stage or event, and (B) transition from a moderate
to advanced disease stage or an event.
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patients with histologic stages I or II, the transition rates
from early to moderate stage at 1, 3, and 5 year(s) were
10.9%, 31.5%, and 43.6%, respectively. The transition
rates were higher for those with stage III or IV: 18.4%,
41.5%, and 60.2% at 1, 3, and 5 year(s), respectively.Table 2. Baseline Factors Associated With the Transition From
Univariate
HR 95%
Male sex 1.27 1.01–
Age at entry, per 10 years 1.06 1.00–
Year of diagnosis, per decade 0.86 0.78–
UDCA use 0.90 0.73–
Bilirubin, ULNa 2.14 1.78–
Albumin, LLN 0.07 0.04–
ALP, ULNa 1.40 1.28–
AST/ALT ratioa 1.33 1.11–
Platelets, per 10-unit increase, 103/mm3 0.98 0.97–
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotr
acid; ULN, upper limit of normal.
aThese biochemical variables were transformed with a natural logarithm.In multivariable analyses, all variables except age at
study entry and year of diagnosis remained significantly
associated with transition to moderate stage (Table 2).
Bilirubin and albumin at a binary split of >0.5 times the
upper limit of normal (ULN) and 1.2 times the ULN,
respectively, were associated significantly with biochem-
ical transition in multivariable analyses (HR, 1.5; 95% CI,
1.3–1.8; P < .001; and HR, 1.6; 95% CI, 1.4–1.9; P < .001,
respectively). The baseline AST/ALT ratio (HR, 1.3; 95%
CI, 1.1–1.5) and ALP levels (HR, 1.3; 95% CI, 1.2–1.5) were
positive predictors of progression, although patients
treated with UDCA had a lower transition rate (HR, 0.70;
95% CI, 0.57–0.86). In addition, ALP levels greater than
1.67 times the ULN was associated with transition to
moderate stage (HR, 1.4; 95%CI, 1.2–1.6) (Supplementary
Figure 2). Bilirubin level, albumin level, ALP level, AST/
ALT ratio, and platelets retained their prognostic value for
biochemical transition in the subgroup of UDCA-treated
patients (Supplementary Table 1).
A total of 242 of 1615 patients with normal albumin
and bilirubin levels at baseline had GLOBE score values
beyond the age-specific GLOBE score threshold. These
patients were more likely to progress to moderate stage
(HR, 1.8; 95% CI, 1.6–2.1) (Supplementary Figure 3).
In subgroup analyses including only histologically
proven early stage patients (stages, I–II), all factors
except platelets and AST/ALT ratio remained as inde-
pendent predictors of transition from early to moderate
biochemical stage (Supplementary Table 2).Factors Associated With Transition From
Biochemical Moderately Advanced to
Advanced Disease Stage
In 904 patients who transitioned to the moderate
stage, univariate analyses showed older age, total bili-
rubin level, albumin level, ALP level, and aminotrans-
ferase levels at the time point of transition to moderate
stage as predictive factors for subsequent transition toBiochemically Early to Moderately Advanced Disease
analyses Multivariate analysesa
CI P HR 95% CI P
1.60 .043 1.27 1.01–1.60 .045
1.12 .044 – – –
0.94 <.001 – – –
1.09 .279 0.70 0.57–0.86 .001
2.58 <.001 1.86 1.53–2.26 <.001
0.12 <.001 0.08 0.04–0.16 <.001
1.55 <.001 1.33 1.20–1.48 <.001
1.58 .002 1.27 1.06–1.53 <.001
0.99 <.001 0.99 0.98–0.99 .007
ansferase; HR, hazard ratio; LLN, lower limit of normal; UDCA, ursodeoxycholic
March 2020 Biochemical Transitions in PBC 689advanced disease (Table 3). In contrast, UDCA-treated
patients and patients with higher platelet levels were
less likely to transition to advanced disease. Although
multivariate analyses rendered age and platelets
nonsignificant, all other variables remained associated
with biochemical transition to advanced stage, with
UDCA associated with a lower probability of transition
(HR, 0.57; 95% CI, 0.40–0.82). ALP levels greater than
1.67 times the ULN were associated significantly with
transition to the advanced stage (HR, 2.5; 95% CI,
1.9–3.3) (Supplementary Figure 2). Albumin levels (bi-
nary split of <1 times the lower limit of normal) were
not associated with biochemical transition whereas bili-
rubin levels (at a binary split of >1 times the ULN; HR,
2.0; 95% CI, 1.4–1.7) were associated with transition to
the advanced stage. Patients with GLOBE score values
higher than the threshold (568 of 904) had higher rates
of progression to advanced disease than those with
GLOBE scores lower than the threshold (HR, 3.0; 95% CI,
2.0–4.3) (Supplementary Figure 3).
Bilirubin level, albumin level, ALP level, and AST/ALT
ratio also were associated with biochemical transition to
the advanced stage in the subgroup of UDCA-treated
patients (Supplementary Table 3).The Impact of Biochemical Transition on Events
During follow-up evaluation, 236 patients developed
at least 1 clinical event: 87 decompensations, 19
hepatocellular carcinomas, 18 LTs, and 112 deaths (21
liver-related deaths) (Figure 1). Overall, the event-free
survival for patients remaining in early biochemical
disease stage at 1, 3, 5, and 10 years was 99.8%, 98.9%,
98.3%, and 93.2%, respectively (Figure 3). Once patients
reached a moderate stage (n ¼ 904), the event-free
survival rates at 1, 3, and 5 year(s) of follow-up evalu-
ation were 97.9%, 95.1%, and 91.5%, respectively. For
patients who consequently transitioned to an advancedTable 3. Factors Associated With the Transition From Biochem
Univariate
HR 95%
Male sex 1.22 0.78–1
Age, per 10 yearsa 1.23 1.11–1
Year of diagnosis, per decadeb 0.86 0.69–1
UDCA use 0.45 0.31–0
Bilirubin, ULNb,c 2.69 2.09–3
Albumin, LLN 0.36 0.15–0
ALP, ULNb,c 2.21 1.80–2
AST/ALT ratiob,c 1.51 1.08–2
Platelets, per 10-unit increase, 103/mm3 0.98 0.96–0
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotr
acid; ULN, upper limit of normal.
aAge at which biochemical moderate stage was reached.
bThese biochemical variables were transformed with a natural logarithm.
cLaboratory parameters correspond to the time point of moderate disease develobiochemical stage (n ¼ 201), these rates were 90.6%,
71.2%, and 58.3%, respectively (Figure 3).
In univariate and multivariate Cox regression, in
which biochemical transition was modeled as a time-
dependent covariate, a higher probability of a clinical
event during follow-up evaluation was found for patients
who transitioned from a biochemical early to moderate
stage (HR, 3.0; 95% CI, 2.0–4.5), from a biochemical
moderate to advanced stage (HR, 4.6; 95% CI, 3.5–6.2),
and overall from an early to advanced disease stage (HR,
14.1; 95% CI, 9.3–21.4; P < .001) (Supplementary
Table 4).
Discussion
In this study of a large cohort of more than 1500 PBC
patients from European and North American centers, we
found that approximately 1 of 2 patients presenting with
an early biochemical disease stage transitioned toward a
moderate biochemical stage within 5 years of follow-up
evaluation. Almost 1 in 6 of these patients who reached
a moderate stage eventually transitioned to an advanced
stage within the next 5 years. These transitions were
associated with an increased risk of clinical events,
underlining the importance of clinical surveillance even
in early stage PBC patients.
We also were able to identify the patients who are
more likely to transition into moderately advanced and
advanced stages. UDCA treatment was associated with
lower rates of biochemical transition (as well as the
composite end point) during follow-up evaluation.
Extended data from several studies have indicated that
UDCA improves the natural history of PBC, even when
administered in the early stages.3,4,8 The GPBCSG
recently showed that UDCA-treated patients have a
lower risk of LT or death than untreated patients, and,
more importantly, the benefit was observed in both re-
sponders and nonresponders.15 Our data point in theically Moderately Advanced to Advanced Disease (n ¼ 904)
analyses Multivariable analyses
CI P HR 95% CI P
.92 .390 – – –
.35 .001 – – –
.05 .119 – – –
.63 <.001 0.57 0.40–0.82 .002
.47 <.001 3.87 3.04–4.94 <.001
.94 .036 0.02 0.01–0.05 < .001
.71 <.001 2.05 1.65–2.54 < .001
.12 .016 1.66 1.17–2.35 .004
.99 <.001 – – –
ansferase; HR, hazard ratio; LLN, lower limit of normal; UDCA, ursodeoxycholic
pment.
Figure 3. Event-free sur-
vival in a clock-reset
approach in patients who
transit from early, to mod-
erate, to advanced
biochemical disease
stage. Patients who did
not transit in biochemical
stage remain in line A.
Patients who transitioned
from early to moderate
stage were switched to a
new survival curve in line
B, which then was reset as
time 0 for their further
follow-up evaluation. Pa-
tients who then transi-
tioned from moderate to
advanced stages were
switched to survival curve
in line C. All hazard ratios
(HR) were obtained by
considering biochemical
transition as a time-
dependent covariate in
Cox regression analyses.
690 Gatselis et al Clinical Gastroenterology and Hepatology Vol. 18, No. 3same direction, by showing UDCA treatment in patients
at an early biochemical stage may reduce progression to
more advanced stages. Taking into account that UDCA is
recommended for all PBC patients including those at
early stages,1 we conducted a subanalysis including only
UDCA-treated patients with similar results in regard to
key risk factors (Supplementary Tables 1 and 3).
Similar to findings in previous studies, ALP levels were
indicative of disease progression. In PBC, ALP is consid-
ered one of themost robustly validatedmarkers of disease
activity. In meta-analyses of 4845 patients, we previously
showed that ALP (>2.0 times the ULN) was associated
strongly with LT and death across various subgroups.16
Moreover, ALP is an important component of most
biochemical criteria that assess treatment response to
UDCA after 1 year of therapy. Our results indicate that
higher ALP levels are associated not onlywith hard clinical
end points, but also with biochemical transition.
In accordance with previous studies, we found
platelet count and the AST/ALT ratio to be associated
with biochemical disease progression, particularly in
patients with advanced histologic stages (III–IV).12,17–22
Platelet count generally is considered a marker of por-
tal hypertension and is of particular importance in
discriminating noncirrhotic from cirrhotic patients with
normal bilirubin and albumin levels. Our results
emphasize the importance of platelet count and the AST/
ALT ratio in identifying PBC patients who are likely to
progress.In contrast to previous studies, male sex was not
associated consistently with disease progression.23–25
One possible explanation for this is that only patients
with mild PBC were included in our study, whereas in a
previous study, the negative impact of male sex appeared
to be limited only to patients with advanced disease.23
Alternatively, the use of the AST/ALT ratio in our
multivariable analyses could have rendered male sex a
nonsignificant factor. Prior studies have documented
relatively higher rates of alcohol consumption in men,
which is characterized by an increased AST/ALT ra-
tio.4,26 This finding coincides with a recent Greek clinical
study, in which, after adjusting for other confounding
factors including alcohol consumption, male sex did not
independently pose a greater risk for disease progres-
sion during follow-up evaluation.27 Of note, in accor-
dance with our findings, a recent study from GPBCSG did
not associate sex with response and transplant-free
survival.28
Strengths of our study were the inclusion of a large
cohort of PBC patients from different geographic areas as
well as long-term follow-up evaluation with many clin-
ical events. This increases the reliability and generaliz-
ability of our results. The GPBCSG database captured all
patient visits and represents the current clinical prac-
tices in the participating centers and the results there-
fore are highly relevant to clinicians working with PBC
patients. Although few laboratory data were missing, the
results presented are based on the imputed databases.
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excluded patients with missing data yielded similar re-
sults (Supplementary Tables 5 and 6). No data on co-
factors (eg, alcohol consumption or obesity) were
available in the GPBCSG database.8,26 However, patients
with alcoholic liver disease were excluded. Nevertheless,
future studies taking into account the aforementioned
cofactors are warranted to identify patient groups with a
high risk of disease progression.
A question that remains is how often we should
perform laboratory examinations in early PBC patients.
Personalized risk stratification, using biochemical
response markers or prognostic models after 1 year of
UDCA therapy, can identify patients at risk of progressive
disease.1 European Association for the Study of the Liver
clinical practice guidelines for PBC recommend that all
patients should have life-long follow-up evaluation,
recognizing that patients have different disease courses
and may require varied levels of attention.1 Patients with
a higher baseline GLOBE score had higher biochemical
transition rates. A baseline GLOBE score calculation
therefore can aid in the identification of patients who
need closer surveillance, even those with early
biochemical stage. Our results also indicate that transi-
tions in biochemical stage are important markers of
disease progression that could be incorporated into
disease staging. Transitions to moderately advanced and
advanced disease stage may justify a change in follow-up
regimen with closer surveillance.
In conclusion, our internationally representative
study provides a comprehensive overview of the natural
history of PBC patients with early disease stage, showing
that almost 1 of 2 patients with early biochemical disease
will transition to moderately advanced disease, and
approximately one sixth of them will progress to the
advanced stage. These transitions are associated with an
increased probability of clinical events. The findings
underline the importance of clinical surveillance in PBC
patients with early biochemical disease stage.
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Exclusion Criteria, and Collected Clinical,
Laboratory, and Histologic Data
Early stage was defined by normal bilirubin and
albumin levels, moderately advanced disease was
defined by an abnormal bilirubin or albumin level, and
advanced disease was defined by abnormal bilirubin
and albumin levels. Exclusion criteria were missing
laboratory data at baseline, unknown start date of
treatment with UDCA and/or last follow-up date, short
follow-up period (<6 months or only baseline visit
available), or a concomitant liver disease including
autoimmune hepatitis/PBC variant and alcoholic liver
disease.
Collected clinical and laboratory data included sex,
age, diagnosis of PBC, liver histology, treatment (type of
medication, dosage, and duration), duration and last dateof follow-up evaluation, baseline antimitochondrial
antibody status, laboratory values (serum ALP, total
bilirubin, albumin, AST, ALT, and platelets), and out-
comes (death and cause of death, liver transplantation,
hepatocellular carcinoma, ascites, variceal bleeding, and
hepatic encephalopathy).
Liver histology performed within 1 year of study
entry or documented cirrhosis before study entry was
classified as a baseline biopsy. Histologic data were
assessed for severity according to the Ludwig et al1 and
Scheuer2 classification.Supplementary References
1. Ludwig J, Dickson ER, McDonald GS. Staging of chronic non-
suppurative destructive cholangitis (syndrome of primary biliary
cirrhosis). Virchows Arch A Pathol Anat Histol 1978;
379:103–112.
2. Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967;
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Supplementary Figure 2. Cumulative incidence of biochemical transition and events stratified by ALP level. Kaplan–Meier
estimates of (A and B) transition from an early to a moderately advanced disease stage or event, and (C and D) transition
from a moderately advanced to advanced disease stage or an event, stratified according to ALP level. ALP, alkaline phos-
phatase; ULN, upper limit of normal.
Supplementary
Figure 1. Flow chart of
patients included in the
study. UDCA, ursodeox-
ycholic acid;
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Supplementary Figure 3. Cumulative incidence of biochemical transition and events stratified by GLOBE score. Kaplan–Meier
estimates of (A and B) transition from an early to a moderately advanced disease stage or event, and (C and D) transition from a
moderately advanced to advanced disease stage or an event, stratified according to GLOBE score.
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Supplementary Table 1. Baseline Factors Associated With the Transition From Biochemically Early to Moderately Advanced
Disease in UDCA-Treated Patients Only (n ¼ 1415)
Univariate analyses Multivariable analysesa
HR 95% CI P HR 95% CI P
Male sex 1.33 1.05–1.70 .02 1.28 0.99–1.64 .057
Age at entry, per 10 years 1.04 0.98–1.11 .176 – – –
Year of diagnosis, per decade 0.88 0.80–0.97 <.01 – – –
Bilirubin level, ULNa 2.05 1.69–2.50 <.001 1.82 1.48–2.25 <.001
Albumin level, LLN 0.07 0.04–0.14 <.001 0.10 0.05–0.20 <.001
ALP level, ULNa 1.33 1.20–1.48 <.001 1.30 1.16–1.46 <.001
AST/ALT ratioa 1.33 1.11–1.61 <.01 1.31 1.08–1.60 .006
Platelets, per 10-unit increase, 103/mm3 0.99 0.99–0.99 <.01 0.99 0.98–0.99 .031
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HR, hazard ratio; LLN, lower limit of normal; ULN, upper normal limit
of normal.
aThese biochemical variables were transformed with a natural logarithm.
Supplementary Table 2. Baseline Factors Associated With the Transition From Biochemically Early to Moderately Advanced
Disease in Patients With Biopsy Stages I or II (n ¼ 623)
Univariate analyses Multivariable analysesa
HR 95% CI P HR 95% CI P
Male sex 1.30 0.91–1.85 .153 – – –
Age at entry, per 10 years 1.06 0.96–1.16 .232 – – –
Year of diagnosis, per decade 0.81 0.68–0.94 .002 0.89 0.75–1.03 .098
UDCA usea 0.93 0.59–1.48 .772 – – –
Bilirubin level, ULNb 1.94 1.43–2.62 <.001 1.75 1.28–1.38 <.001
Albumin level, LLN 0.12 0.04–0.38 <.001 0.14 0.05–0.41 <.001
ALP level, ULNb 1.35 1.15–1.58 <.001 1.23 1.05–1.45 .012
AST/ALT ratiob 1.21 0.90–1.61 .208 – – –
Platelets, per 10-unit increase, 103/mm3 0.99 0.98–1.01 .366 – – –
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HR, hazard ratio; LLN, lower limit of normal; UDCA, ursodeoxycholic
acid; ULN, upper normal limit of normal.
aUDCA was not entered into the multivariable analysis because only 34 patients were not treated with UDCA.
bThese biochemical variables were transformed with a natural logarithm.
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Supplementary Table 3. Factors Associated With the Transition From Biochemically Moderately Advanced to Advanced
Disease in UDCA-Treated Patients Only (n ¼ 794)
Univariate analyses Multivariable analysesa
HR 95% CI P HR 95% CI P
Male sex 1.38 0.85–2.22 .192 – – –
Age at entry, per 10 yearsa 1.19 1.06–1.33 .011 – – –
Year of diagnosis, per decade 0.89 0.68–1.10 .276 – – –
Bilirubin level, ULNb,c 2.57 1.95–3.40 <.001 3.74 2.88–4.85 <.001
Albumin level, LLNc 0.39 0.14–1.10 .076 0.02 0.01–0.06 <.001
ALP level, ULNb,c 1.94 1.54–2.44 <.001 1.98 1.54–2.53 <.001
AST/ALT ratiob,c 1.43 0.98–2.09 .067 1.72 1.14–2.59 .004
Platelets, per 10-unit increase, 103/mm3 0.99 0.99–1.00 .239 – – –
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HR, hazard ratio; LLN, lower limit of normal; UDCA, ursodeoxycholic
acid; ULN, upper normal limit of normal.
aAge at which biochemical moderate stage was reached.
bThese biochemical variables were transformed with a natural logarithm.
cLaboratory parameters correspond to the time point of moderate disease development.
Supplementary Table 4. The Association of Time-Dependent Transition With Clinical Events
Univariate analyses Multivariable analyses
HR 95% CI P HR 95% CI P
Moderate vs early biochemical stagea 3.37 2.28–4.97 <.001 3.05 2.06–4.51 <.001
Advanced vs moderate biochemical stagea 5.38 4.05–7.13 <.001 4.63 3.47–6.17 <.001
Advanced vs early biochemical stagea 18.12 12.10–27.12 <.001 14.11 9.32–21.36 <.001
Male sex 1.30 0.85–1.98 .224 – – –
UDCA treatment 0.49 0.36–0.68 <.001 – – –
Age at entry, per 10 years 1.57 1.43–1.68 <.001 1.42 1.29–1.55 <.001
Year of diagnosis, per decade 0.79 0.62–0.96 .006 – – –
Bilirubin level, ULNb 1.94 1.35–2.79 <.001 – – –
Albumin level, LLN 0.18 0.06–0.57 <.001 – – –
ALP level, ULNb 1.56 1.28–1.89 <.001 1.85 1.17–2.95 .009
AST/ALT ratiob 1.79 1.28–2.52 <.001 – – –
Platelets, per 10-unit increase, 103/mm3 0.96 0.95–0.98 <.001 0.98 0.97–0.99 .045
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HR, hazard ratio; LLN, lower limit of normal; UDCA, ursodeoxycholic
acid; ULN, upper normal limit of normal.
aHR was obtained by considering biochemical transition as a time-dependent covariate.
bThese biochemical variables were transformed with a natural logarithm.
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Supplementary Table 5. Baseline Factors Associated With the Transition From Biochemically Early to Moderately Advanced
Disease in the Original Data Set
N
Univariate analyses Multivariable analysesa
HR 95% CI P HR 95% CI P
Male sex 1615 1.27 1.01-1.60 .043 – – –
Age at entry, per 10 years 1615 1.06 1.00-1.12 .044 – – –
Year of diagnosis, per decade 1615 0.86 0.78-0.94 <.001 – – –
UDCA use 1615 0.90 0.73-1.09 .279 0.67 0.45–1.01 .057
Bilirubinb 1615 2.14 1.78-2.58 <.001 1.84 1.46–2.31 <.001
Albumin 1615 0.07 0.04-0.12 <.001 0.04 0.02–0.09 <.001
ALP, ULNb 1486 1.44 1.30–1.60 <.001 1.20 1.05–1.36 .002
AST, ULNb 1406 1.44 1.26–1.65 <.001
ALT, ULN 1338 1.15 1.03–1.29 .015
AST/ALT ratio 1322 1.37 1.12–1.67 .002 – – –
Platelets, per 10-unit increase 1202 0.98 0.97–0.99 <.001 0.99 0.99–0.99 .011
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HR, hazard ratio; LLN, lower limit of normal; UDCA, ursodeoxycholic
acid; ULN, upper normal limit of normal.
aThis model was constructed for 1042 patients with complete data on all variables.
bThese biochemical variables were transformed with a natural logarithm.
Supplementary Table 6. The Association of Time-Dependent Transition With Clinical Events in Original Data Set
N
Univariate analyses Multivariable analysesa
HR 95% CI P HR 95% CI P
Moderate vs early biochemical stagea 1615 3.37 2.28–4.97 <.001 2.54 1.58–4.09 <.001
Advanced vs moderate biochemical stagea 1615 5.38 4.05–7.13 <.001 4.09 2.83–5.93 <.001
Advanced vs early biochemical stagea 1615 18.12 12.10–27.12 <.001 10.42 6.23–17.42 <.001
Male sex 1615 1.30 0.85–1.98 .224 – – –
UDCA treatment 1615 0.49 0.36–0.68 <.001 – – –
Age at entry, per 10 years 1615 1.57 1.43–1.68 <.001 1.56 1.40–1.72 <.001
Year of diagnosis, per decade 1615 0.79 0.62–0.96 .006 – – –
Bilirubin, ULNb 1615 1.94 1.35–2.79 <.001 – – –
Albumin, LLN 1615 0.18 0.06–0.57 <.001 – – –
ALP, ULNc 1486 1.59 1.31–1.95 <.001 1.56 1.19–2.04 .001
AST, ULNc 1406 1.49 1.14–1.93 .003
ALT, ULNc 1338 1.06 0.84–1.33 .637
AST/ALT ratioc 1322 1.92 1.30–2.82 .001 – – –
Platelets, per 10-unit increase 1202 0.96 0.94–0.98 <.001 0.97 0.95–0.99 .007
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HR, hazard ratio; LLN, lower limit of normal; UDCA, ursodeoxycholic
acid; ULN, upper normal limit of normal.
aThis model was constructed for 1042 patients with complete data on all variables.
bHR was obtained by considering biochemical transition as a time-dependent covariate.
cThese biochemical variables were transformed with a natural logarithm.
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